CapTem plus Y-90 for liver-spread neuroendocrine tumors
Part of Cancer clinical trials.
This Phase 2 study tests whether combining capecitabine/temozolomide (“CapTem”) with Y-90 treatment can shrink neuroendocrine tumor (NET) spread in the liver. It may help people whose tumor is mostly in the liver and cannot be fully removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+) with a confirmed grade 2 or 3 well-differentiated neuroendocrine tumor.
- Your liver has measurable metastases (at least one spot bigger than 1 cm), and at least half of the tumor burden is in the liver.
- Your liver tumor burden must not be more than 50% of your liver volume, and you must have a main portal vein that is open (not blocked).
- You should not have had chemotherapy or radiation in the last 4 weeks, and you need enough energy/function (ECOG 0–2).
- Your bloodwork and organs must be strong enough (good liver tests, enough platelets, kidney function within limits, and acceptable blood clotting).
- You must be able to have imaging planning (CT and contrast-enhanced MRI) and—if chosen—Y-90 treatment planning with angiography simulation that can be safely completed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a cancer drug called tirapazamine, given along with a liver artery procedure (embolization) to treat liver-dominant metastatic neuroendocrine tumors. It aims to find a safe dose and see whether the combination can better control tumor growth in the liver.
This Phase 2 study tests a gentler, steady schedule of temozolomide in people with advanced low-grade neuroendocrine neoplasms who are “unfit” for stronger treatments. The goal is to shrink or control the cancer while being safer for people with weaker health or organ function.
This trial tests a combination of targeted radiation (Y-90), chemotherapy (capecitabine), and immunotherapy (atezolizumab) for people with colorectal cancer that has spread mainly to the liver and is no longer responding to at least two prior treatments. The goal is to see if this combination can shrink tumors or slow the disease.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This Phase 2 study tests whether combining cabozantinib with temozolomide can control advanced lung or gastrointestinal neuroendocrine tumors that have grown after prior treatments. It also closely monitors safety, including blood counts, organ function, and other side effects.
This trial tests combining Yttrium-90 microspheres (tiny radioactive beads delivered into the liver), immunotherapy (drugs that help your immune system fight cancer), and anti-angiogenesis drugs (medicines that block blood supply to tumors) followed by a liver-directed chemotherapy infusion. It is designed for people with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery yet may become operable after this treatment.
Hear when a new Neuroendocrine Tumor Grade 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.